Locus coeruleus modulates neuroinflammation in parkinsonism and dementia

Locus Coeruleus (LC) is the main noradrenergic nucleus of the central nervous system, and its neurons widely innervate the whole brain. LC is severely degenerated both in Alzheimer’s disease (AD) and in Parkinson’s disease (PD), years before the onset of clinical symptoms, through mechanisms that differ among the two disorders. Several experimental studies have shown that noradrenaline modulates neuroinflammation, mainly by acting on microglia/astrocytes function. In the present review, after a brief introduction on the anatomy and physiology of LC, we provide an overview of experimental data supporting a pathogenetic role of LC degeneration in AD and PD. Then, we describe in detail experimental data, obtained in vitro and in vivo in animal models, which support a potential role of neuroinflammation in such a link, and the specific molecules (i.e., released cytokines, glial receptors, including pattern recognition receptors and others) whose expression is altered by LC degeneration and might play a key role in AD/PD pathogenesis. New imaging and biochemical tools have recently been developed in humans to estimate in vivo the integrity of LC, the degree of neuroinflammation, and pathology AD/PD biomarkers; it is auspicable that these will allow in the near future to test the existence of a link between LC-neuroinflammation and neurodegeneration directly in patients

The degeneration of locus coeruleus occurring during Alzheimer’s disease clinical progression: a neuroimaging follow-up investigation

\ua9 The Author(s) 2024.The noradrenergic nucleus Locus Coeruleus (LC) is precociously involved in Alzheimer’s Disease (AD) pathology, and its degeneration progresses during the course of the disease. Using Magnetic Resonance Imaging (MRI), researchers showed also in vivo in patients the disruption of LC, which can be observed both in Mild Cognitively Impaired individuals and AD demented patients. In this study, we report the results of a follow-up neuroradiological assessment, in which we evaluated the LC degeneration overtime in a group of cognitively impaired patients, submitted to MRI both at baseline and at the end of a 2.5-year follow-up. We found that a progressive LC disruption can be observed also in vivo, involving the entire nucleus and associated with clinical diagnosis. Our findings parallel neuropathological ones, which showed a continuous increase of neuronal death and volumetric atrophy within the LC with the progression of Braak’s stages for neurofibrillary pathology. This supports the reliability of MRI as a tool for exploring the integrity of the central noradrenergic system in neurodegenerative disorders

Overview of the marine litter status in the Atlantic Area: floating litter

CleanAtlantic is an INTERREG Atlantic Area Programme project that aimed at protecting biodiversity and ecosystem services in the Atlantic Area by improving capabilities to monitor, prevent and remove (macro) marine litter. Besides, the project also contributed to raise awareness and change attitudes among stakeholders and to improve marine litter managing systems. To achieve these aims, the work was organised in 8 work packages. The present deliverable aims at synthesizing the main results achieved on the frame of the action 1 of work package 4, which focused on the Regional characterisation of marine litter in the Atlantic Area. More specifically, this report deals with the assessment of the floating litter data available in this area. Additionally, the major key findings, gaps on monitoring and research as well as potential improvements and recommendations are identified

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients (n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA (n = 2343, 12.1%) were older, more disabled and with a faster progression to severe disability (p < 0.0001), than those identified by the ND (n = 3868, 20.0%). In both groups, the most consistent risk factors (p < 0.05) for SPMS were a multifocal onset, an age at onset >40 years, higher baseline EDSS score and a higher number of relapses; the most consistent protective factor was the disease-modifying therapy (DMT) exposure. DMT exposure during SP did not impact the risk of reaching irreversible EDSS 6.0. Conclusion: A DDA definition of SPMS identifies more aggressive progressive patients. DMT exposure reduces the risk of SPMS conversion, but it does not prevent the disability accumulation after the SP transition

Overview of the marine litter status in the Atlantic Area: beach, floating and seabed litter

CleanAtlantic is an INTERREG Atlantic Area Programme project that aimed at protecting biodiversity and ecosystem services in the Atlantic Area by improving capabilities to monitor, prevent and remove (macro) marine litter. Besides, the project also contributed to raise awareness and change attitudes among stakeholders and to improve marine litter managing systems. To achieve these aims, the work was organised in 8 work packages. The present deliverable aims at synthesizing the main results obtained on the frame of the action 1 of work package 4, which focused on the Regional characterisation of marine litter in the Atlantic Area. With this purpose, an overview of marine litter status in beach, floating and seabed compartments in the Atlantic Area is presented. Additionally, the major key findings, gaps on monitoring and research as well as potential improvements and recommendations are identified. Links to the complete dedicated reports for each compartment are included in the references section. Also, an interactive map for spatial visualization of data on beach, floating and seabed litter composition and abundance in the Atlantic Area was created and is presented at the end of this report

The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.

Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS